SciELO - Scientific Electronic Library Online

 
vol.75 suppl.1Factores epidemiológicos y evolución clínica de pacientes hospitalizados por bronquiolitis aguda en dos hospitales de SantiagoEvaluación de la respuesta broncodilatadora en pacientes secuelados de adenovirus índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista chilena de pediatría

versión impresa ISSN 0370-4106

Resumen

ASTUDILLO O., Pedro et al. MDI salbutamol in wheezy infants: An eficcacy and safety comparison study. Rev. chil. pediatr. [online]. 2004, vol.75, suppl.1, pp.32-36. ISSN 0370-4106.  http://dx.doi.org/10.4067/S0370-41062004000700006.

Many pharmaceutical companies comercialize generic salbutamol (GS) in metered-dose inhalers in Chile. However, the equivalence in eficcacy and safety of the GS has not been compared with the original salbutamol (OS) in children less than two years. In a prospective study we studied 115 infants (1-23 months) presenting a moderate or severe acute wheezing episode. They were randomly allocated to receive GS (Cipla, India) or OS (GSK, England) in a protocol of treatment according Chilean National Guidelines. At the end of the first hour of observation, the treatment was successful (score = 5) in 88.1% (52/59) of GS group and 87,5% (49/56) of OS group, non significant difference. Groups were not different in mean clinical score, respiratory frequency, pulse oximetry and cardiac frequency. Mean score fell 2,70 points in GS group and 2,64 points in OS group. At the end of the second hour, treatment was not successful in 5,1% (3/59) in GS group and 5,4% (3/56) in OS group. None of these parameters were statistically different. This study shows that GS and OS are similar in efficacy and safety in the treatment of acute wheezing in infants

Palabras clave : wheezy; infants; salbutamol; tratment; MDI.

        · resumen en Español     · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons